Helicobacter Pylori eradication therapy: getting research into practice.

Hdl Handle:
http://hdl.handle.net/10147/323791
Title:
Helicobacter Pylori eradication therapy: getting research into practice.
Authors:
McDonnell, R; O'Morain, C; Boland, M; Culhane, A; Johnson, Z; Johnson, H; Murray, F; Doyle, D
Affiliation:
Eastern Regional Health Authority, Health Information Unit, Department of Public Health, Dr Steeven's Hospital, Dublin 8, Ireland. bob.mcdonnell@erha.ie
Citation:
McDonnell R et al. Helicobacter Pylori eradication therapy: getting research into practice. Ir Med J. 2003;96(1):13-6
Journal:
Irish medical journal
Issue Date:
Jan-2003
URI:
http://hdl.handle.net/10147/323791
PubMed ID:
12617436
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/12617436
Abstract:
Helicobacter Pylori (H. Pylori) is the primary cause of duodenal ulcer (DU). Guidelines recommend that all patients with DU be considered for Helicobacter Pylori Eradication Therapy (HPET). However, the proportion of patients with DU on long term anti-ulcer medication receiving HPET is small. This study examined the effectiveness of the continuing medical education (CME) network of the Irish College of General Practitioners (ICGP) in promoting best practice in DU treatment among GPs in an eastern region of Ireland. Ninty eight GPs recruited from the CME network of the ICGP were randomised in two cohorts. Cohort 1 received an (early) intervention; GPs were asked to identify their patients with DU receiving long term anti-ulcer medication and prescribe HPET according to defined criteria. Cohort 2 received the intervention later. Prescribing of HPET was monitored using routine prescribing data. Twenty per cent (286/1,422) of patients in cohort 1 and 19.2% (127/661) in cohort 2 had a DU. After exclusions, 53% (152/286) in cohort 1 and 30.7% (39/127) in cohort 2, were eligible for HPET. A significantly higher proportion of patients in cohort 1 received HPET compared with cohort 2 during the early intervention period (13.8% vs 0.0%, p<0.05). Reasons for not prescribing HPET included concurrent illness in patients, failure to comply with treatment. Best practice guidelines on HPET treatment of DU can be successfully applied using CME networks. This model could be repeated in another therapeutic area where established research is not yet current practice.
Item Type:
Article
Language:
en
Description:
Helicobacter Pylori (H. Pylori) is the primary cause of duodenal ulcer (DU). Guidelines recommend that all patients with DU be considered for Helicobacter Pylori Eradication Therapy (HPET). However, the proportion of patients with DU on long term anti-ulcer medication receiving HPET is small. This study examined the effectiveness of the continuing medical education (CME) network of the Irish College of General Practitioners (ICGP) in promoting best practice in DU treatment among GPs in an eastern region of Ireland. Ninty eight GPs recruited from the CME network of the ICGP were randomised in two cohorts. Cohort 1 received an (early) intervention; GPs were asked to identify their patients with DU receiving long term anti-ulcer medication and prescribe HPET according to defined criteria. Cohort 2 received the intervention later. Prescribing of HPET was monitored using routine prescribing data. Twenty per cent (286/1,422) of patients in cohort 1 and 19.2% (127/661) in cohort 2 had a DU. After exclusions, 53% (152/286) in cohort 1 and 30.7% (39/127) in cohort 2, were eligible for HPET. A significantly higher proportion of patients in cohort 1 received HPET compared with cohort 2 during the early intervention period (13.8% vs 0.0%, p<0.05). Reasons for not prescribing HPET included concurrent illness in patients, failure to comply with treatment. Best practice guidelines on HPET treatment of DU can be successfully applied using CME networks. This model could be repeated in another therapeutic area where established research is not yet current practice.
Keywords:
INFECTION CONTROL; GENERAL PRACTICE
Local subject classification:
ULCER, DUODENAL
MeSH:
Algorithms; Anti-Ulcer Agents; Cohort Studies; Duodenal Ulcer; Education, Medical, Continuing; Helicobacter pylori; Humans; Ireland; Physicians, Family; Practice Guidelines as Topic; Research; Treatment Outcome
ISSN:
0332-3102

Full metadata record

DC FieldValue Language
dc.contributor.authorMcDonnell, Ren_GB
dc.contributor.authorO'Morain, Cen_GB
dc.contributor.authorBoland, Men_GB
dc.contributor.authorCulhane, Aen_GB
dc.contributor.authorJohnson, Zen_GB
dc.contributor.authorJohnson, Hen_GB
dc.contributor.authorMurray, Fen_GB
dc.contributor.authorDoyle, Den_GB
dc.date.accessioned2014-07-25T09:50:14Z-
dc.date.available2014-07-25T09:50:14Z-
dc.date.issued2003-01-
dc.identifier.citationMcDonnell R et al. Helicobacter Pylori eradication therapy: getting research into practice. Ir Med J. 2003;96(1):13-6en_GB
dc.identifier.issn0332-3102-
dc.identifier.pmid12617436-
dc.identifier.urihttp://hdl.handle.net/10147/323791-
dc.descriptionHelicobacter Pylori (H. Pylori) is the primary cause of duodenal ulcer (DU). Guidelines recommend that all patients with DU be considered for Helicobacter Pylori Eradication Therapy (HPET). However, the proportion of patients with DU on long term anti-ulcer medication receiving HPET is small. This study examined the effectiveness of the continuing medical education (CME) network of the Irish College of General Practitioners (ICGP) in promoting best practice in DU treatment among GPs in an eastern region of Ireland. Ninty eight GPs recruited from the CME network of the ICGP were randomised in two cohorts. Cohort 1 received an (early) intervention; GPs were asked to identify their patients with DU receiving long term anti-ulcer medication and prescribe HPET according to defined criteria. Cohort 2 received the intervention later. Prescribing of HPET was monitored using routine prescribing data. Twenty per cent (286/1,422) of patients in cohort 1 and 19.2% (127/661) in cohort 2 had a DU. After exclusions, 53% (152/286) in cohort 1 and 30.7% (39/127) in cohort 2, were eligible for HPET. A significantly higher proportion of patients in cohort 1 received HPET compared with cohort 2 during the early intervention period (13.8% vs 0.0%, p<0.05). Reasons for not prescribing HPET included concurrent illness in patients, failure to comply with treatment. Best practice guidelines on HPET treatment of DU can be successfully applied using CME networks. This model could be repeated in another therapeutic area where established research is not yet current practice.en_GB
dc.description.abstractHelicobacter Pylori (H. Pylori) is the primary cause of duodenal ulcer (DU). Guidelines recommend that all patients with DU be considered for Helicobacter Pylori Eradication Therapy (HPET). However, the proportion of patients with DU on long term anti-ulcer medication receiving HPET is small. This study examined the effectiveness of the continuing medical education (CME) network of the Irish College of General Practitioners (ICGP) in promoting best practice in DU treatment among GPs in an eastern region of Ireland. Ninty eight GPs recruited from the CME network of the ICGP were randomised in two cohorts. Cohort 1 received an (early) intervention; GPs were asked to identify their patients with DU receiving long term anti-ulcer medication and prescribe HPET according to defined criteria. Cohort 2 received the intervention later. Prescribing of HPET was monitored using routine prescribing data. Twenty per cent (286/1,422) of patients in cohort 1 and 19.2% (127/661) in cohort 2 had a DU. After exclusions, 53% (152/286) in cohort 1 and 30.7% (39/127) in cohort 2, were eligible for HPET. A significantly higher proportion of patients in cohort 1 received HPET compared with cohort 2 during the early intervention period (13.8% vs 0.0%, p<0.05). Reasons for not prescribing HPET included concurrent illness in patients, failure to comply with treatment. Best practice guidelines on HPET treatment of DU can be successfully applied using CME networks. This model could be repeated in another therapeutic area where established research is not yet current practice.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/12617436en_GB
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.subjectINFECTION CONTROLen_GB
dc.subjectGENERAL PRACTICEen_GB
dc.subject.meshAlgorithms-
dc.subject.meshAnti-Ulcer Agents-
dc.subject.meshCohort Studies-
dc.subject.meshDuodenal Ulcer-
dc.subject.meshEducation, Medical, Continuing-
dc.subject.meshHelicobacter pylori-
dc.subject.meshHumans-
dc.subject.meshIreland-
dc.subject.meshPhysicians, Family-
dc.subject.meshPractice Guidelines as Topic-
dc.subject.meshResearch-
dc.subject.meshTreatment Outcome-
dc.subject.otherULCER, DUODENALen_GB
dc.titleHelicobacter Pylori eradication therapy: getting research into practice.en_GB
dc.typeArticleen
dc.contributor.departmentEastern Regional Health Authority, Health Information Unit, Department of Public Health, Dr Steeven's Hospital, Dublin 8, Ireland. bob.mcdonnell@erha.ieen_GB
dc.identifier.journalIrish medical journalen_GB

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.